scholarly journals Venovenous Extracorporeal CO2 removal to support ultraprotective ventilation in moderate-severe ARDS: A systematic review and meta-analysis of the literature

2021 ◽  
Author(s):  
Elliott Worku ◽  
Daniel Brodie ◽  
Ryan Ruiyang Ling ◽  
Kollengode Ramanathan ◽  
Alain Combes ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Systematic Review ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Meta Analysis ◽  
Protective Ventilation ◽  
Driving Pressure ◽  
List Type ◽  
Extracorporeal Carbon Dioxide Removal ◽  
Ultraprotective Ventilation

AbstractBackgroundA strategy that limits tidal volumes and inspiratory pressures, improves outcomes in patients with the acute respiratory distress syndrome (ARDS). Extracorporeal carbon dioxide removal (ECCO2R) may facilitate ultra-protective ventilation. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of venovenous ECCO2R in supporting ultra-protective ventilation in moderate-to-severe ARDS.MethodsMEDLINE and EMBASE were interrogated for studies (2000-2021) reporting venovenous ECCO2R use in patients with moderate-to-severe ARDS. Studies reporting ≥10 adult patients in English language journals were included. Ventilatory parameters after 24 hours of initiating ECCO2R, device characteristics, and safety outcomes were collected. The primary outcome measure was the change in driving pressure at 24 hours of ECCO2R therapy in relation to baseline. Secondary outcomes included change in tidal volume, gas exchange, and safety data.ResultsTen studies reporting 421 patients (PaO2:FiO2 141.03mmHg) were included. Extracorporeal blood flow rates ranged from 0.35-1.5 L/min. Random effects modelling indicated a 3.56 cmH2O reduction (95%-CI: 3.22-3.91) in driving pressure from baseline (p<0.001) and a 1.89 ml/kg (95%-CI: 1.75-2.02, p<0.001) reduction in tidal volume. Oxygenation, respiratory rate and PEEP remained unchanged. No significant interactions between driving pressure reduction and baseline driving pressure, partial pressure of arterial carbon dioxide or PaO2:FiO2 ratio were identified in metaregression analysis. Bleeding and haemolysis were the commonest complications of therapy.ConclusionsVenovenous ECCO2R permitted significant reductions in ΔP in patients with moderate-to-severe ARDS. Heterogeneity amongst studies and devices, a paucity of randomised controlled trials, and variable safety reporting calls for standardisation of outcome reporting.Prospective evaluation of optimal device operation and anticoagulation in high quality studies is required before further recommendations can be made.Key MessagesWhat is the Key Question?In adult patients with moderate-to-severe acute respiratory distress syndrome (ARDS), can venovenous extracorporeal carbon dioxide removal (ECCO2R) support ultraprotective lung ventilation beyond the current standard for protective ventilation in ARDS?What is the bottom line?Systematic review of available data on venovenous ECCO2R shows that it can reduce driving pressure in ventilated patients with moderate-to-severe ARDS, supporting ultraprotective ventilation. Prospective measurement of mechanical power, and greater emphasis on safety and patient-centred outcomes is needed.Why read on?This is the first systematic review to exclusively address venovenous ECCO2R use in the moderate-to-severe ARDS cohort. We report the degree of lung protection achieved with venovenous ECCO2R devices, along with factors potentially limiting widespread adoption.

Intraoperative Management of Hypercapnia with an Extracorporeal Carbon Dioxide Removal Device during Giant Bullectomy

2016 ◽  
Vol 11 (2) ◽  
pp. 142-145 ◽  
Author(s):  
Andrea Dell'Amore ◽  
Rocco D'Andrea ◽  
Guido Caroli ◽  
Carlo Alberto Mazzoli ◽  
Alberto Rocca ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Protective Ventilation ◽  
Lung Protective Ventilation ◽  
Extracorporeal Carbon Dioxide Removal ◽  
Intraoperative Management ◽  
Ventilation Strategies ◽  
Ultraprotective Ventilation ◽  
Compromised Patients

Extracorporeal CO2-removal devices have been introduced in clinical practice to provide protective and ultraprotective ventilation strategies in different settings to avoid retention of carbon dioxide. The need to facilitate lung-protective ventilation is required not only for the treatment of acute respiratory distress syndrome but also in thoracic surgery during complex operations, especially in respiratory compromised patients. This report describes a case of giant bullectomy for vanishing lung syndrome in which intraoperative hypercapnia secondary to protective ventilation was managed with a CO2-removal device (Decap-Hemodec s.r.l., Salerno, Italy). To the best of our knowledge, this is the first report in the literature of the intraoperative use of the Decap system for giant bullectomy.

Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study

Thorax ◽  
2019 ◽  
Vol 74 (12) ◽  
pp. 1179-1181 ◽  
Author(s):  
Alain Combes ◽  
Tommaso Tonetti ◽  
Vito Fanelli ◽  
Tai Pham ◽  
Antonio Pesenti ◽  
...  
Keyword(s):  
Carbon Dioxide ◽  
Blood Flow ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Secondary Analysis ◽  
Efficacy And Safety ◽  
Extracorporeal Carbon Dioxide Removal ◽  
Membrane Area ◽  
Extraction Capacity ◽  
Ultraprotective Ventilation

Retrospective analysis of the SUPERNOVA trial exploring the hypothesis that efficacy and safety of extracorporeal carbon dioxide removal (ECCO2R) to facilitate reduction of tidal volume (VT) to 4 mL/kg in patients with acute respiratory distress syndrome (ARDS) may differ between systems with lower (area of membrane length 0.59 m2; blood flow 300–500 mL/min) and higher (membrane area 1.30 m2; blood flow between 800 and 1000 mL/min) CO2 extraction capacity. Ninety-five patients with moderate ARDS were included (33 patients treated with lower and 62 patients treated with higher CO2 extraction devices). We found that (1) VT of 4 mL/kg was reached by 55% and 64% of patients with the lower extraction versus 90% and 92% of patients with higher extraction devices at 8 and 24 hours from baseline, respectively (p<0.001), and (2) percentage of patients experiencing episodes of ECCO2R-related haemolysis and bleeding was higher with lower than with higher extraction devices (21% vs 6%, p=0.045% and 27% vs 6%, p=0.010, respectively). Although V T of 4 mL/kg could have been obtained with all devices, this was achieved frequently and with a lower rate of adverse events by devices with higher CO2 extraction capacity.

scholarly journals Cardiac biomarkers in acute respiratory distress syndrome: a systematic review and meta-analysis

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Dilip Jayasimhan ◽  
Simon Foster ◽  
Catherina L. Chang ◽  
Robert J. Hancox
Keyword(s):  
Systematic Review ◽  
Acute Respiratory Distress Syndrome ◽  
Intensive Care ◽  
Cardiac Dysfunction ◽  
Distress Syndrome ◽  
Troponin I ◽  
Meta Analysis ◽  
Cardiac Injury ◽  
Cardiac Biomarkers ◽  
Risk Of Death

Abstract Background Acute respiratory distress syndrome (ARDS) is a leading cause of morbidity and mortality in the intensive care unit. Biochemical markers of cardiac dysfunction are associated with high mortality in many respiratory conditions. The aim of this systematic review is to examine the link between elevated biomarkers of cardiac dysfunction in ARDS and mortality. Methods A systematic review of MEDLINE, EMBASE, Web of Science and CENTRAL databases was performed. We included studies of adult intensive care patients with ARDS that reported the risk of death in relation to a measured biomarker of cardiac dysfunction. The primary outcome of interest was mortality up to 60 days. A random-effects model was used for pooled estimates. Funnel-plot inspection was done to evaluate publication bias; Cochrane chi-square tests and I2 tests were used to assess heterogeneity. Results Twenty-two studies were included in the systematic review and 18 in the meta-analysis. Biomarkers of cardiac stretch included NT-ProBNP (nine studies) and BNP (six studies). Biomarkers of cardiac injury included Troponin-T (two studies), Troponin-I (one study) and High-Sensitivity-Troponin-I (three studies). Three studies assessed multiple cardiac biomarkers. High levels of NT-proBNP and BNP were associated with a higher risk of death up to 60 days (unadjusted OR 8.98; CI 4.15-19.43; p<0.00001). This association persisted after adjustment for age and illness severity. Biomarkers of cardiac injury were also associated with higher mortality, but this association was not statistically significant (unadjusted OR 2.21; CI 0.94-5.16; p= 0.07). Conclusion Biomarkers of cardiac stretch are associated with increased mortality in ARDS.

Sign in / Sign up

Export Citation Format

Share Document